Mavacamten by Bristol-Myers Squibb is a new breath for all patients with obstructive hypertrophic cardiomyopathy.
New Drugs
Novel drugs approved by regulators for human use.
A drug is positioned as new if it:
- offers treatment for a disease for which no specific therapy previously existed
- targets a new therapeutic target
- has a new mechanism of action
- is developed in a new formulation, optimized or improved
- is part of a new combination drug
- belongs to a new class of drug compounds.
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Tepezza: First Drug for Thyroid Eye Disease
Teprotumumab by Horizon Therapeutics can really help with proptosis and diplopia in Graves’ disease and beyond.
Posted inNeuroscience, New Drugs, Regulatory
Oligomannate: Finally New Drug to Treat Alzheimer’s Disease
Innovative Chinese medicine eliminates gut microbiota dysbiosis, and it helps slow the progression of dementia in Alzheimer’s disease.
Posted inNew Drugs, Rare/Orphan Diseases, Regulatory
Vijoice: First Targeted Treatment for PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis and its alpelisib will help with very rare diseases with malformations and excessive tissue growth.
Posted inNeuroscience, New Drugs, Regulatory
Igalmi: New Drug for Agitation in Schizophrenia and Bipolar Disorder
BioXcel Therapeutics has offered a fast-action mouth-dissolving sublingual film formulation of dexmedetomidine.
Posted inMetabolism, New Drugs, Regulatory
Twymeeg: Completely New Drug for Treatment of Type 2 Diabetes Mellitus
Imeglimin is a universal anti-diabetic drug that incorporates the power of all existing glucose-lowering drugs.
Posted inMetabolism, New Drugs, Regulatory
Kerendia: New Drug for Diabetic Kidney Disease
Finerenone for the treatment of diabetic nephropathy, a chronic kidney disease associated with type 2 diabetes mellitus.